Understanding Daicel Corporation Structure and Performance

Daicel Corporation is a Japanese chemical company that operates through a multi-layered structure. This structure includes subsidiaries, affiliates, and joint ventures.

Daicel Corporation has a diverse portfolio of products and services, including pharmaceuticals, functional materials, and food ingredients. Its pharmaceutical business is its largest segment.

Daicel Corporation's pharmaceutical business is a significant contributor to its overall revenue. In fact, it accounts for over 50% of the company's total sales.

Daicel Corporation's functional materials segment includes products such as odor control agents and humidity control agents. These products are used in a variety of applications, including air purification systems and construction materials.

For your interest: International Business Companies Act

Daicel Corporation is a publicly traded company listed on the Tokyo Stock Exchange under the ticker symbol 4202.

The ownership of Daicel is quite diverse, with a mix of institutional and individual shareholders. As of March 2023, institutional investors hold a significant 50.2% of shares, while foreign investors hold around 20.5% and domestic individual investors hold approximately 19.3%.

Daicel's ownership structure has seen fluctuations over the past five years, with institutional investors increasing their stake from 45% in 2018 to the current 50.2%. This trend suggests growing confidence from institutional investors in Daicel's strategic initiatives and market position.

The largest institutional shareholders of Daicel include BlackRock, Inc., The Vanguard Group, Inc., Nomura Asset Management, and Sumitomo Mitsui Trust Holdings. These companies hold significant stakes in Daicel, with BlackRock, Inc. owning 7.5% of shares and The Vanguard Group, Inc. owning 5.3%.

Here's a breakdown of Daicel's major shareholders as of 2023:

Daicel's financial performance has been on the rise in recent years. In the fiscal year ending March 2023, the company reported total revenues of approximately ¥326 billion (around $2.4 billion).

The company's net income for the same period was recorded at ¥22 billion (approximately $160 million), reflecting a year-over-year increase of 8%. This growth in net income is a positive sign for Daicel's financial health.

Check this out: Capital Power Income

Daicel's earnings per share (EPS) for the fiscal year 2023 stood at ¥70, an increase from ¥65 in the previous year. This increase in EPS suggests that Daicel's profitability is improving.

Here's a comparison of Daicel's financial performance between 2026 and 2027, based on projected data:

As you can see, Daicel's projected sales and net income are expected to increase in 2027 compared to 2026. However, the company's net debt is expected to remain relatively stable.

Daicel's market value has also been growing, with a market value of approximately ¥371 billion (around $2.43 billion) in 2023. This growth in market value is likely due to the company's improving financial performance and increasing profitability.

A different take: Rivian Enterprise Value

Daicel's business operations are a key part of its success, with the company reporting consolidated net sales of approximately ¥475 billion in fiscal year 2023.

The company's operational segments can be categorized into four main areas: Chemicals, Plastics, Advanced Components, and Food Packaging.

Daicel invests heavily in research and development, with an R&D budget of approximately ¥18 billion for 2023, which accounts for about 3.8% of total sales.

Here's a breakdown of Daicel's operational segments:

International sales are a significant contributor to Daicel's revenue, making up around 40% of total revenue in fiscal year 2023.

Daicel has a strong global presence, with manufacturing facilities in North America, Europe, and Asia, and aims to enhance its global reach through strategic partnerships and acquisitions.

For your interest: List of Largest Companies by Revenue

Daicel has been making headlines with its recent announcements. The company plans to absorb Polyplastics to streamline its engineering plastics operations.

In October, Daicel Corporation announced a reorganization plan involving a company split with a consolidated subsidiary. This move is expected to optimize its business with technical plastics.

Daicel has also been actively buying back its own shares. In December, the company repurchased 6.8 million shares, and in July, it announced plans to buy back up to 12 million shares.

Here's a summary of Daicel's recent share buybacks:

Daicel's financial performance has also been noteworthy. In the first half of the fiscal year, the company's attributable profit increased by nearly 8%.

Daicel Corporation has been making headlines recently with several significant announcements.

Daicel plans to integrate Polyplastics to optimize its business with technical plastics, as reported on October 16th.

The company has also announced a corporate restructuring plan, which includes the separation of a consolidated subsidiary, on the same day.

Daicel Corporation will repurchase its own shares, amounting to 3.61% of the outstanding shares, on May 22nd.

The company has declared a dividend for the fiscal year ending on March 31, 2025, payable on June 23, 2025.

Here's a summary of the recent announcements:

Daicel Corporation has also made a few other significant announcements, including the acquisition of Daicel Novafoam Ltd. by Jigyo Shokei Kiko Co., Ltd. on March 28th.

Daicel Corporation has announced a reorganization plan involving a company split with a consolidated subsidiary, which was announced on October 16th.

The plan aims to streamline engineering plastics operations by absorbing Polyplastics, another company under the Daicel Group.

A unique perspective: SCAN Health Plan

Daicel Corporation's reorganization plan involves a company split, with Polyplastics splitting under the Daicel Group's plan.

A notice regarding the group reorganization plan was released on October 16th, detailing the company split with a consolidated subsidiary.

Here are the key dates related to the reorganization plan:

You can find more information about the reorganization plan in Daicel Corporation's notice, which is available as a PDF document.

At Daicel Corporation, the management team is led by Yasuhiro Sakaki, who serves as the CEO and Chairman of the Board of Directors at the age of 63.

The company's Chief Technology Officer is Toshio Shiwaku, a 62-year-old executive who has been with the company since June 2024.

Kotaro Sugimoto, also 65 years old, holds the position of PRN and has been with the company since June 2011.

Yoshimi Ogawa, a 65-year-old executive, chairs the Board of Directors, while Teisuke Kitayama, 79 years old, and Kotaro Sugimoto, 65 years old, serve as directors.

Here's a brief overview of the key executives at Daicel:

Daicel's recent financial performance is impressive, with total revenues of approximately ¥326 billion in fiscal year 2023.

The company's net income for the same period was recorded at ¥22 billion, reflecting a year-over-year increase of 8%. This growth is a testament to Daicel's strong financial health.

Daicel's earnings per share (EPS) for fiscal year 2023 stood at ¥70, an increase from ¥65 in the previous year. This indicates a steady and consistent growth in the company's profitability.

As of October 2023, Daicel Corporation's market capitalization is approximately ¥500 billion, which is around $3.7 billion.

Curious to learn more? Check out: Growth Stocks Can Be Profitable Because They

Daicel Corporation's market capitalization is approximately ¥500 billion, as of October 2023, which is equivalent to around $3.7 billion.

This significant market value indicates the company's size and scope, making it a substantial player in its industry.

The stock has demonstrated volatility, with a price-to-earnings (P/E) ratio of 22.4, which suggests investor expectations for future growth.

Daicel Corp made a significant announcement on October 16th, revealing a corporate restructuring plan. This plan involves the separation of a consolidated subsidiary.

For your interest: Tufts Health Plan Ppo

The company's goal is to optimize its business with technical plastics by integrating the Polyplastics plant. This move is expected to have a positive impact on Daicel's operations.

Daicel Corp will be undergoing a major reorganization, with the aim of creating a more streamlined and efficient structure. The company's leadership is committed to making this change a success.

Here's a brief overview of the key events surrounding Daicel's restructuring plan: